Male breast cancer: A special therapeutic problem. Anything new? (Review)

Gennari, R; Curigliano, Giuseppe; Jereczek-Fossa, Barbara A.; Zurrida, Stefano; Renne, Giuseppe; Intra, Mattia; Galimberti, Viviana; Luini, Alberto; Orecchia, Roberto; Viale, Giuseppe; Goldhrisch, Aron; Veronesi, Umberto

doi:10.3892/ijo.24.3.663

Cited by 50 publications

(93 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In general, therapies for male breast cancer have been adopted from female breast cancer, and surgery and radiotherapy, usually in combination, have been the main treatments throughout the study period (Buzdar, 2003;Gennari et al, 2004) with chemotherapy increasing towards the end. The present data should be of high quality, as they were carefully controlled by the participating, well-established cancer registries.…”

Section: Discussionmentioning

confidence: 99%

Second primary malignancies in patients with male breast cancer

et al. 2005

View full text Add to dashboard Cite

An international multicentre study of first and second primary neoplasms associated with male breast cancer was carried out by pooling data from 13 cancer registries. Among a total of 3409 men with primary breast cancer, 426 (12.5%) developed a second neoplasia; other than breast cancer, a 34% overall excess risk of second primary neoplasia, affecting the small intestine (standardised incidence ratio, 4.95, 95% confidence interval, 1.35 -12.7), rectum (1.78, 1.20 -2.54), pancreas (1.93, 1.14 -3.05), skin (nonmelanoma, 1.65, 1.16 -2.29), prostate (1.61, 1.34 -1.93) and lymphohaematopoietic system (1.63, 1.12 -2.29). A total of 225 male breast cancers was recorded after cancers other than breast cancer, but an increase was found only after lymphohaematopoietic neoplasms. BRCA2 (and to some extent BRCA1) mutations may explain the findings for pancreatic and prostate cancers. Increases at other sites may be related to unknown factors or to chance. This large study shows that the risks for second discordant tumours after male breast cancer pose only a moderate excess risk. It is well established that women with a first primary breast cancer run a 2 -5-fold increased risk of developing second primary breast cancer compared with the risk for the first primary breast cancer (Chen et al, 1999;Vaittinen and Hemminki, 2000). In men, the risk of second breast cancer after a first breast cancer is much higher, of the order of 100 (Dong and Hemminki, 2001;Auvinen et al, 2002), despite the overall pathology, natural history and hormonal risk factors for sporadic and familial breast cancers showing certain similarities for both genders; socioeconomic risk factors also appear similar for male and female breast cancers (Hsing et al, 1998;Hemminki and Li, 2003;Hemminki et al, 2003b). Klinefelter syndrome, gynaecomastia and testicular disease are additional male risk factors (Hultborn et al, 1997;Lynch et al, 1999). Heritable mutations predisposing to male breast cancer include BRCA2, BRCA1 and, possibly, the androgen receptor gene (Lynch et al, 1999;Liede et al, 2004). Accounting for some 15% of all cases, BRCA2 mutations are the most common heritable factors in male breast cancer, and, in addition to breast cancer, carriers have an increased risk of prostate, pancreatic and stomach cancers and melanomas (Liede et al, 2004). BRCA1 mutations are less common in male than female breast cancer, and also affect prostate cancer (Liede et al, 2004). Few studies have assessed the risk of second cancers, other than breast cancer, among male breast cancer patients and melanoma appears to the be the only tumour showing an excess among men (Auvinen et al, 2002;Hemminki and Granstrom, 2002).In the present study, the risks of second primary neoplasms for first male breast cancer, and for male breast cancer following any other cancer are based on pooled data from 13 large cancer registries, which are collaborating in studies on second primary neoplasms. As a result, the study is two times larger than the previous largest study (Auvinen et al, 20...

show abstract

Section: Discussionmentioning

confidence: 99%

Second primary malignancies in patients with male breast cancer

et al. 2005

View full text Add to dashboard Cite

show abstract

“…A mutação que acomete o gene BRCA2 é a mais comum e pode estar presente em 4 a 40% dos casos. Os tumores associados a essas mutações tendem a acometer pacientes mais jovens e, portanto, têm prognós-tico desfavorável 4,8 .…”

Section: Fatores Genéticosunclassified

“…São exemplos: homens com exposição profissional crônica a altas temperaturas e trabalhadores em indústrias químicas, de sabão e perfumes 4,8,10 . Existem ainda evidências em relação à exposição profissional à gasolina e em homens que trabalham em empresas de fumo 4,8 . Na literatura existem relatos de que, em consequência da exposição a campos eletromagnéticos, ocorre a formação de tumores mamários em animais, por causa da inibição da glândula pineal, com diminuição da melatonina.…”

Section: Fatores Ambientaisunclassified

“…Nesta situação, existem relatos até do desenvolvimento de câncer de mama bilateral 8 . Em relação ao risco associado com o estrogênio endógeno, as evidências são mistas.…”

Section: Fatores Hormonaisunclassified

“…As taxas de prevalência variam geograficamente, sendo maiores na África, em países como Zâmbia e Egito (variando entre 5 e 15 casos a cada 100 mil habitantes), onde causas infecciosas endêmicas provocam dano hepático e hiperestrogenismo secundário 3 . A frequência está entre 1 para cada 100.000 habitantes nos países da Europa e dos Estados Unidos, sendo menor em países como Japão (menos de 5 casos por um milhão de habitantes) 4,7,8 . Homens judeus apresentam maiores taxas de incidência, independentemente do local onde vivem (2 a 3 casos por 100.000/habitantes ao ano).…”

Section: Introductionunclassified

See 2 more Smart Citations

Câncer de mama em homens

Nogueira¹,

Mendonça²,

Pasqualette³

2014

Rev. Bras. Mastol.

View full text Add to dashboard Cite

Keywords RESUMOO câncer de mama em homens é uma doença pouco conhecida. Sua abordagem em ensaios clínicos e publicações é pouco frequente. Foi realizada uma revisão da literatura, priorizando a epidemiologia, os fatores de risco, a patologia e os marcadores tumorais da doença. Corresponde a 1% de todas as neoplasias da mama. Os fatores de risco incluem hiperestrogenismo, idade, ascendência judaica, história familiar e síndrome de Klinefelter. Cerca de 90% dos tumores são ductais invasivos. De 80 a 90% dos casos apresentam receptores de estrógeno e progesterona positivos. O tratamento é semelhante ao do câncer de mama na mulher: cirurgia, hormonioterapia, quimioterapia e radioterapia são usadas, seguindo os guidelines femininos. Os fatores prognós-ticos incluem tamanho tumoral, grau histológico e comprometimento linfonodal. O câncer de mama é similar em homens e mulheres; todavia, os casos masculinos apresentam particularidades imuno-histoquímicas, mas não existem estudos suficientes para avaliar o impacto dessa característica no prognóstico e tratamento dessa neoplasia. ABSTRACT Breast cancer in men is a little known disease. His approach in clinical trials

show abstract

Das Mammakarzinom beim Mann

Hofer

Schmalfeldt

Gschwend

et al. 2010

Urologe

View full text Add to dashboard Cite

Male breast cancer (male BC) accounts for <1% of all cancers in men, showing an increasing incidence with a peak in the sixth decade. Overall, men experience a worse prognosis than women, probably due to an advanced stage together with the higher age at diagnosis of male patients. Major risk factors for developing male BC include clinical disorders involving hormonal imbalances (excess of estrogen or a deficiency of testosterone as seen in patients with Klinefelter syndrome) and a positive family history for breast cancer. About 90% of male BC are invasive ductal carcinomas. Standard treatment for localized cancer is surgical removal. Adjuvant radiation and systemic therapy are the same as in women with breast cancer. Male BC expresses hormone receptors in about 90% of cases; therefore, tamoxifen is a therapeutic option. A future challenge for the urologist or andrologist is to diagnose the disease at an early stage to improve prognosis.

show abstract

Male breast cancer: A special therapeutic problem. Anything new? (Review)

Cited by 50 publications

References 0 publications

Second primary malignancies in patients with male breast cancer

Second primary malignancies in patients with male breast cancer

Câncer de mama em homens

Das Mammakarzinom beim Mann

Contact Info

Product

Resources

About